Aurora Spine (ASG) Q3 2025 earnings summary

Executive summary

• Q3 2025 results were moderate, with sales exceeding $4.4 million for the fifth consecutive quarter, and momentum improved through the quarter, culminating in a record revenue month in October.

• Management is focused on expanding proprietary product offerings, especially minimally invasive solutions, building the internal sales force, and educating the market on new technologies.

• Commercial launches of Hydra ARO and Dexa L/DEXA-L began initial sales and are expected to drive future growth, with positive early feedback and ongoing physician onboarding.

• Transition away from third-party lumbar screw systems to proprietary products is nearly complete, aligning with strategic goals.

Financial highlights

• Q3 2025 revenue was $4.43 million, down 7.1% year-over-year from $4.77 million, mainly due to lower lumbar sales during the product transition.

• Gross margin improved slightly to 60.9% from 60.5% in Q3 2024, supported by a shift to proprietary and direct sales.

• Operating expenses were $2.81 million, flat year-over-year, with higher marketing spend offset by lower G&A and consulting fees.

• EBITDAC was $165,600, down from $380,117 in Q3 2024 but up from $142,000 in Q2 2025.

• Net loss was $842,000, compared to net income of $71,000 in Q3 2024 and a loss of $199,000 in Q2 2025; another source reports a net loss of $142,000.

Outlook and guidance

• October 2025 was the best revenue month on record, attributed to new product launches and expanded approvals.

• Management expects continued growth as more physicians adopt Hydra ARO and Dexa L, with additional kits and disposables planned for 2026.

• Revenue is expected to average over $1.5 million per month for the remainder of the year if current trends continue.

• Capital structure is considered sufficient for budget needs through 2026, with ongoing improvements in cash collections.

• Management is optimistic about future prospects, focusing on expanding sales territories and market education.